Arachchi A, et al. - Considering the recent PBS listing of infliximab for acute severe ulcerative colitis (ASUC), researchers investigated the durability of response to IFX as medical salvage therapy in IBD center, and if it is beneficial in terms of health care utilization compared with colectomy. They searched IBD clinic databases and identified 120 ASUC cases, who having failed corticosteroid therapy, were given either infliximab or colectomy as first-line therapy. Outcomes suggest that in reducing colectomy risk, increased induction has an additional benefit to a single dose IFX. They noted greater than 50% chance of preventing colectomy and reducing TLOS with IFX PBS funded doses.